Analysis of genomic mutation and immunohistochemistry of platelet-derived growth factor receptors in canine vascular tumours

Veterinary and Comparative Oncology

Volumn 13, Issue 3, 2015, Pages 237-245

  Abou Asa, S ^a,c   Mori, T ^a,b   Maruo, K ^a,b   Khater, A ^c   El sawak, A ^a   Abd el Aziz, E ^c   Yanai, T ^a   Sakai, H ^a,b  

^a GIFU UNIVERSITY   (Japan)

^b GIFU UNIVERSITY   (Japan)

^c KAFRELSHEIKH UNIVERSITY   (Egypt)

Author keywords

Dog; Hemangioma; Hemangiosarcoma; Immunohistochemistry; Mutation; PDGFR

Indexed keywords

CANIS FAMILIARIS;

PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PRIMER DNA; PROTEIN TYROSINE KINASE;

ANGIOSARCOMA; ANIMAL; DOG; DOG DISEASE; FEMALE; GENETICS; HEMANGIOMA; IMMUNOHISTOCHEMISTRY; JAPAN; MALE; MUTATION; POLYMERASE CHAIN REACTION; VASCULAR TUMOR; VETERINARY;

ANIMALS; DNA PRIMERS; DOG DISEASES; DOGS; FEMALE; HEMANGIOMA; HEMANGIOSARCOMA; IMMUNOHISTOCHEMISTRY; JAPAN; MALE; MUTATION; POLYMERASE CHAIN REACTION; PROTEIN-TYROSINE KINASES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; VASCULAR NEOPLASMS;

EID: 84939653158     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/vco.12035     Document Type: Article

References (34)

1. Weiss SW and Goldblum JR. Malignant vascular tumors. In: Enzinger and Weiss's Soft Tissue Tumors. 5th edn., SW Weiss and JR Goldblum Eds., Maryland Heights, MO, Mosley Elsevier, 2008: 703-732.
2. Cohen SM, Storer RD, Criswell KA, Doerrer NG, Dellarco VL, Pegg DG, Wojcinski ZW, Malarkey DE, Jacobs AC, Klaunig JE, Swenberg JA and Cook JC. Hemangiosarcoma in rodents: mode-of-action evaluation and human relevance. Toxicological Sciences 2009; 111: 4-18.
3. Heldin CH and Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiological Reviews 1999; 79: 1283-1300.
4. Mao X and Hamoudi RA. Molecular and cytogenetic analysis of glioblastoma multiforme. Cancer Genetics and Cytogenetics 2000; 122: 87-92.
5. MacDonald TJ, Brown KM, LaFleur B, Peterson K, Lawlor C, Chen Y, Packer RJ, Cogen P and Stephan DA. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nature Genetics 2001; 29: 143-152.
6. Oda Y, Wehrmann B, Radig K, Walter H, Röse I, Neumann W and Roessner A. Expression of growth factors and their receptors in human osteosarcomas. Immunohistochemical detection of epidermal growth factor, platelet-derived growth factor and their receptors: its correlation with proliferating activities and p53 expression. General & Diagnostic Pathology 1995; 141: 97-103.
7. Yang SY and Xu GM. Expression of PDGF and its receptor as well as their relationship to proliferating activity and apoptosis of meningiomas in human meningiomas. Journal of Clinical Neurosciences 2001; 8: 49-53.
8. Mayer TJ, Frauenhoffer EE and Meyers AC. Expression of epidermal growth factor and platelet-derived growth factor receptors during cervical carcinogenesis. In Vitro Cellular & Developmental Biology - Animal 2000; 36: 667-676.
9. Coltrera MD, Wang J, Porter PL and Gown AM. Expression of platelet-derived growth factor B-chain and the platelet-derived growth factor receptor beta subunit in human breast tissue and breast carcinoma. Cancer Research 1995; 55: 2703-2708.
10. Henriksen R, Funa K, Wilander E, Bäckström T, Ridderheim M and Oberg K. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Research 1993; 53: 4550-4554.
11. Schmandt RE, Broaddus R, Lu KH, Shvartsman H, Thornton A, Malpica A, Sun C, Bodurka DC and Gershenson DM. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer 2003; 98: 758-764.
12. Matei D, Chang DD and Jeng MH. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation. Clinical Cancer Research 2004; 10: 681-690.
13. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD and Fletcher JA. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708-710.
14. Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y and Kitamura Y. Gain-of-function mutations of platelet derived growth factor receptor α gene in gastrointestinal stromal tumors. Gastroenterology 2003; 125: 660-667.
15. Abou Asa S, Murai A, Murakami M, Hoshino Y, Mori T, Maruo K, Khater A and El-Sawak A. el-Aziz EA, Yanai T and Sakai H. Expression of platelet-derived growth factor and its receptors in spontaneous canine hemangiosarcoma and cutaneous hemangioma. Histology and Histopathology 2012; 27: 601-607.
16. Kubo T, Piperdi S, Rosenblum J, Antonescu CR, Chen W, Kim H, Huvos AG, Sowers R, Meyers PA, Healey JH and Gorlick R. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer 2008; 112: 2119-2129.
17. Grone A, Fonfara S, Markus S and Baumgartner W. RT-PCR amplification of various canine cytokines and so-called house-keeping genes in a species-specific macrophage cell line (DH82) and canine peripheral blood leukocytes. Journal of Veterinary Medicine Series B 1999; 46: 301-310.
18. Pietras K, Sjöblom T, Rubin K, Heldin CH and Ostman A. PDGF receptors as cancer drug targets. Cancer Cell 2003; 3: 439-443.
19. Sihto H, Sarlomo-Rikala M, Tynninen O, Tanner M, Andersson LC, Franssila K, Nupponen NN and Joensuu H. KIT and platelet derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. Journal of Clinical Oncology 2005; 23: 49-57.
20. Longley BJ, Reguera MJ and Ma Y. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leukemia Research 2001; 25: 571-576.
21. Lasota J, Jasinski M, Sarlomo-Rikala M and Miettinen M. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. American Journal of Pathology 1999; 154: 53-60.
22. Chan PM, Ilangumaran S, La RJ, Chakrabartty A and Rottapel R. Autoinhibition of the Kit receptor tyrosine kinase by the cytosolic juxtamembrane region. Molecular Cell Biology 2003; 23: 3067-3078.
23. Carroll M, Tomasson MH, Barker GF, Golub TR and Gilliland DG. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proceedings of the National Academy of Sciences of the United States of America 1996; 93: 14845-14850.
24. Betsholtz C, Westermark B, Ek B and Heldin CH. Coexpression of a PDGF-like growth factor and PDGF receptors in a human osteosarcoma cell line: implications for autocrine receptor activation. Cell 1984; 39: 447-457.
25. Black P, Carroll R and Glowacka D. Expression of platelet-derived growth factor transcripts in medulloblastomas and ependymomas. Pediatric Neurosurgery 1996; 24: 74-78.
26. Apte SM, Bucana CD, Killion JJ, Gershenson DM and Fidler IJ. Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. Gynecologic Oncology 2004; 93: 78-86.
27. Pietras K. Increasing tumor uptake of anticancer drugs with imatinib. Seminar in Oncology 2004; 31: 18-23.
28. Kindler T, Breitenbuecher F, Marx A, Beck J, Hess G, Weinkauf B, Duyster J, Peschel C, Kirkpatrick CJ, Theobald M, Gschaidmeier H, Huber C and Fischer T. Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood 2004; 103: 3644-3654.
29. Yonemori K, Tsuta K, Ando M, Hirakawa A, Hatanaka Y, Matsuno Y, Chuman H, Yamazaki N, Fujiwara Y and Hasegawa T. Contrasting prognostic implications of platelet-derived growth factor receptor-β and vascular endothelial growth factor receptor-2 in patients with angiosarcoma. Annals of Surgical Oncology 2011; 18: 2841-2850.
30. Tamborini E, Miselli F, Negri T, Lagonigro MS, Staurengo S, Dagrada GP, Stacchiotti S, Pastore E, Gronchi A, Perrone F, Carbone A, Pierotti MA, Casali PG and Pilotti S. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas. Clinical Cancer Research 2006; 12: 6920-6928.
31. Carvalho I, Milanezi F, Martins A, Reis RM and Schmitt F. Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Research 2005; 7: R788-R795.
32. Taja-Chayeb L, Chavez-Blanco A, Martínez-Tlahuel J, González-Fierro A, Candelaria M, Chanona-Vilchis J, Robles E and Dueñas-Gonzalez A. Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer. Cancer Cell International 2006; 6: 22.
33. Liegl B, Leithner A, Bauernhofer T, Windhager R, Guelly C, Regauer S and Beham A. Immunohistochemical and mutational analysis of PDGF and PDGFR in desmoid tumours: is there a role for tyrosine kinase inhibitors in c-kit-negative desmoid tumours? Histopathology 2006; 49: 576-581.
34. Rossi G, Cavazza A, Marchioni A, Longo L, Migaldi M, Sartori G, Bigiani N, Schirosi L, Casali C, Morandi U, Facciolongo N, Maiorana A, Bavieri M, Fabbri LM and Brambilla E. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFR-α, PDGFR-β, and Met in large-cell neuroendocrine carcinoma of the lung. Journal of Clinical Oncology 2005; 23: 8774-8785.